CD274 and neoplasm: Currently, PD-L1 expression on tumor cells assessed by immunohistochemistry is the only approved diagnosis biomarker for immunotherapy in patients with NSCLC and has been shown to be related with the efficacy of immune checkpoint inhibitors (ICIs) in NSCLC.